XML 134 R82.htm IDEA: XBRL DOCUMENT
v3.24.0.1

License and Collaboration Agreements (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended
--- | --- | ---
Jan. 31, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Specified royalty term |  | 10 years |  |
Research and development expense |  | $ 265,868 | $ 286,408 | $ 573,306
Maximum additional milestone payments |  | 2,202,100 |  |
GSK |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Sales-based milestone payment |  | 12,000 |  | 8,000
Maximum additional milestone payments |  | 16,000 |  |
Novocure |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Maximum additional milestone payments |  | 68,000 |  |
Deciphera |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Maximum additional milestone payments |  | 173,000 |  |
Novo Holdings |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Maximum additional milestone payments |  | $ 40,500 |  |
argenx |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Issuance of ordinary shares in connection with collaboration and license arrangement (in shares) | 5,681,820 |  |  |
Upfront payment | $ 62,300 |  |  |
Amgen |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Specified royalty term |  | 10 years |  |
Maximum additional milestone payments |  | $ 37,000 |  |
Innoviva |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Maximum additional milestone payments |  | 88,600 |  |
BMS | Repotrectinib |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Maximum additional milestone payments |  | 141,000 |  |
BMS | Adagrasib |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Maximum additional milestone payments |  | 263,000 |  |
Upfront payment |  |  |  | 65,000
Development milestone payment |  |  | 10,000 |
BMS | Xanomeline-Trospium |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Maximum additional milestone payments |  | 142,000 |  |
Pfizer |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Maximum additional milestone payments |  | 263,000 |  |
Other counterparties |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Upfront payment |  | 10,000 |  |
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | GSK |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Research and development expense |  |  | 4,000 |
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Deciphera |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Research and development expense |  |  |  | 5,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Novo Holdings |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Research and development expense |  |  |  | 6,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | argenx |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Research and development expense |  |  |  | 100,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Innoviva |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Research and development expense |  | 3,000 |  |
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | BMS | Repotrectinib |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Research and development expense |  | $ 5,000 |  | 5,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | BMS | Xanomeline-Trospium |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Research and development expense |  |  | 10,000 | $ 35,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Pfizer |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Research and development expense |  |  | $ 30,000 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Rights and Obligations, Development Milestone Payment + References No definition available. + Details
Name: | zlab_CollaborativeArrangementRightsAndObligationsDevelopmentMilestonePayment
Namespace Prefix: | zlab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount represents the additional milestone payments. + References No definition available. + Details
Name: | zlab_CollaborativeArrangementRightsAndObligationsMaximumAdditionalMilestonePayments
Namespace Prefix: | zlab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Payment of upfront fees for license agreement. + References No definition available. + Details
Name: | zlab_CollaborativeArrangementRightsAndObligationsPaymentOfUpFrontFeesForLicenseAgreement
Namespace Prefix: | zlab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangement, Rights and Obligations, Sales-Based Milestone Payment + References No definition available. + Details
Name: | zlab_CollaborativeArrangementRightsAndObligationsSalesBasedMilestonePayment
Namespace Prefix: | zlab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Rights and Obligations, Specified Royalty Term + References No definition available. + Details
Name: | zlab_CollaborativeArrangementRightsAndObligationsSpecifiedRoyaltyTerm
Namespace Prefix: | zlab_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_NovocureLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_DecipheraPharmaceuticalsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_GurnetPointCapitalAndNovoHoldingsASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_ArgenxBvMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_AmgenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_InnovivaInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_BMSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=zlab_RepotrectinibMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=zlab_AdagrasibMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=zlab_XanomelineTrospiumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_PfizerIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_OtherCounterpartiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |